Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S4II
|
|||
| Former ID |
DCL000407
|
|||
| Drug Name |
GSK1292263
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Gastric adenocarcinoma [ICD-11: 2B72] | Phase 2 | [1] | |
| Type-2 diabetes [ICD-11: 5A11] | Phase 2 | [1] | ||
| Company |
GSK
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H28N4O4S
|
|||
| Canonical SMILES |
CC(C)C1=NOC(=N1)N2CCC(CC2)COC3=CN=C(C=C3)C4=CC=C(C=C4)S(=O)(=O)C
|
|||
| InChI |
1S/C23H28N4O4S/c1-16(2)22-25-23(31-26-22)27-12-10-17(11-13-27)15-30-19-6-9-21(24-14-19)18-4-7-20(8-5-18)32(3,28)29/h4-9,14,16-17H,10-13,15H2,1-3H3
|
|||
| InChIKey |
AYJRTVVIBJSSKN-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1032823-75-8
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glucose-dependent insulinotropic receptor (GPR119) | Target Info | Modulator | [2] |
| KEGG Pathway | cAMP signaling pathway | |||
| Insulin secretion | ||||
| WikiPathways | Incretin Synthesis, Secretion, and Inactivation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01218204) A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin.U.S. National Institutes of Health. | |||
| REF 2 | Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.PLoS One.2014 Apr 3;9(4):e92494. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.